Sugi Predict

Sugi Predict / Compounds / SCHEMBL4783237

SCHEMBL4783237

SCHEMBL4783237

COc1ccc2c(c1)c(Nc1cccc(Cl)c1)nn2C(C)C(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FADS1 O60427 2/20 0.48
▸ LMNA P02545 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ GFER P55789 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ AKR1C3 P42330 2/20 0.47
▸ AKR1C2 P52895 2/20 0.47
▸ MAPT P10636 3/20 0.44
▸ CSNK2A2 P19784 2/20 0.42
▸ CSNK2B P67870 2/20 0.42
▸ CSNK2A1 P68400 2/20 0.42
▸ KDR P35968 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ ELANE P08246 1/20 0.41
▸ GPR35 Q9HC97 1/20 0.41
▸ EGFR P00533 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4787408 0.88 FADS1 (0.51) FADS1LMNAMEN1HPGDGFER
SCHEMBL4785824 0.86 FADS1 (0.51) FADS1LMNAMEN1HPGDGFER
SCHEMBL4739358 0.84 FADS1 (0.53) FADS1LMNAMEN1HPGDGFER
SCHEMBL4783753 0.81 FADS1 (0.52) FADS1LMNAMEN1HPGDGFER
SCHEMBL4741035 0.81 MEN1 (0.50) FADS1LMNAMEN1HPGDGFER
SCHEMBL4741979 0.81 FADS1 (0.48) FADS1LMNAMEN1HPGDGFER
SCHEMBL4741006 0.81 FADS1 (0.51) FADS1LMNAMEN1HPGDGFER
SCHEMBL4741937 0.78 FADS1 (0.45) FADS1LMNAMEN1HPGDGFER
SCHEMBL4742030 0.77 MAPT (0.52) FADS1LMNAMEN1HPGDGFER
SCHEMBL4934407 0.77 AURKA (0.49) FADS1LMNAMEN1HPGDGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 — — WO claimed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 — — WO claimed
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC BUCK INST RES AGING (US) 2024-07-04 — — US disclosed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 — — US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 — — US disclosed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 FADS1 1059/4885LMNA 1776/4885MEN1 3245/4885
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC DAGLA, DAGLB, MGLL FADS1 192/4885LMNA 163/4885MEN1 3106/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG FADS1 270/4885LMNA 682/4885MEN1 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.